- Home
- FBIOP vs RDUS Comparison
FBIOP vs RDUS Comparison
Compare FBIOP & RDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- RDUS
- Stock Information
- Founded
- FBIOP N/A
- RDUS 1906
- Country
- FBIOP United States
- RDUS United States
- Employees
- FBIOP 186
- RDUS N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- RDUS Industrial Specialties
- Sector
- FBIOP Health Care
- RDUS Consumer Discretionary
- Exchange
- FBIOP Nasdaq
- RDUS Nasdaq
- Market Cap
- FBIOP N/A
- RDUS N/A
- IPO Year
- FBIOP N/A
- RDUS 1993
- Fundamental
- Price
- FBIOP $6.98
- RDUS $12.74
- Analyst Decision
- FBIOP
- RDUS Hold
- Analyst Count
- FBIOP 0
- RDUS 2
- Target Price
- FBIOP N/A
- RDUS $22.00
- AVG Volume (30 Days)
- FBIOP N/A
- RDUS 335.0K
- Earning Date
- FBIOP N/A
- RDUS 01-07-2025
- Dividend Yield
- FBIOP N/A
- RDUS 5.96%
- EPS Growth
- FBIOP N/A
- RDUS N/A
- EPS
- FBIOP N/A
- RDUS N/A
- Revenue
- FBIOP N/A
- RDUS $2,722,332,000.00
- Revenue This Year
- FBIOP N/A
- RDUS $5.38
- Revenue Next Year
- FBIOP N/A
- RDUS $2.63
- P/E Ratio
- FBIOP N/A
- RDUS N/A
- Revenue Growth
- FBIOP N/A
- RDUS N/A
- 52 Week Low
- FBIOP N/A
- RDUS $10.57
- 52 Week High
- FBIOP N/A
- RDUS $27.70
- Technical
- Relative Strength Index (RSI)
- FBIOP 56.58
- RDUS 35.82
- Support Level
- FBIOP $6.75
- RDUS $10.76
- Resistance Level
- FBIOP $6.97
- RDUS $15.50
- Average True Range (ATR)
- FBIOP 0.38
- RDUS 0.80
- MACD
- FBIOP -0.02
- RDUS -0.11
- Stochastic Oscillator
- FBIOP 70.37
- RDUS 38.14
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.